TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Kuros Biosciences ( (CH:KURN) ).
Kuros Biosciences announced a 77% year-over-year increase in revenue for the first nine months of 2025, driven by strong sales of its MagnetOs products. The company has launched the MagnetOs MIS Delivery System in the U.S., following FDA clearance, and received approval for MagnetOs products in Saudi Arabia, marking significant milestones in its strategic expansion and positioning in the medical device industry.
The most recent analyst rating on (CH:KURN) stock is a Hold with a CHF25.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a leader in innovative biologic technologies, with operations in the United States, Switzerland, and the Netherlands. The company is listed on the SIX Swiss Exchange and focuses on developing advanced bone graft products, such as MagnetOs, which is used globally in various medical procedures.
Average Trading Volume: 223,493
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.12B
Find detailed analytics on KURN stock on TipRanks’ Stock Analysis page.